Condition: Relapsing Multiple Sclerosis · Sponsor: TG Therapeutics, Inc.
The primary objective of the lactation study is to characterize the presence and concentration of BRIUMVI™ in breast milk among breastfeeding participants who receive BRIUMVI™ therapeutically for the treatment of relapsing forms of multiple sclerosis (RMS).
This description comes directly from the study's public registry record.
PROVIDE Virtual Research Coordination Center · 1-877-296-4411 · briumvi_lactationstudy@ppd.com
Always discuss trial participation with your own doctor first.
| PROVIDE Virtual Research Coordination Center | San Francisco, California, United States | Recruiting |
| PROVIDE Virtual Research Coordination Center | Smyrna, Georgia, United States | Recruiting |
| TG Therapeutics Investigational Trial Site | Boston, Massachusetts, United States | Recruiting |
| PROVIDE Virtual Research Coordination Center | Wilmington, North Carolina, United States | Recruiting |
| PROVIDE Virtual Research Coordination Center | Nashville, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06143514